TGAT
CNWKk
Market cap7mUSD
Oct 21, Last price
1.80EUR
Name
CoDon AG
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Established in 1993 and headquartered in Teltow, Germany, co.don AG operates as a global biopharmaceutical firm dedicated to the research, development, and marketing of cell-based pharmaceutical solutions. The company's core focus is on joint preservation and the regenerative repair of articular cartilage defects. Its offerings include Spherox, an advanced three-dimensional chondrocyte product specifically designed to address cartilage damage in adult knee joints. Additionally, co.don AG provides co.don chondrosphere, a therapy utilized for treating cartilage imperfections in younger patients across multiple joints, such as the hip, ankle, shoulder, elbow, and knees. These specialized treatments are primarily employed by orthopedic and trauma surgeons.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | ||||||
Unusual Expense (Income) | ||||||
NOPBT | ||||||
NOPBT Margin | ||||||
Operating Taxes | ||||||
Tax Rate | ||||||
NOPAT | ||||||
Net income | ||||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | ||||||
Long-term debt | ||||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | ||||||
| Cash flow | ||||||
Cash from operating activities | ||||||
CAPEX | ||||||
Cash from investing activities | ||||||
Cash from financing activities | ||||||
FCF | ||||||
| Balance | ||||||
Cash | ||||||
Long term investments | ||||||
Excess cash | ||||||
Stockholders' equity | ||||||
Invested Capital | ||||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | ||||||
Price | ||||||
Market cap | ||||||
EV | ||||||
EBITDA | ||||||
EV/EBITDA | ||||||
Interest | ||||||
Interest/NOPBT | ||||||